IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3…

By P. Paschka, R. Schlenk, V. Gaidzik, Marianne Habdank, J. Krönke, L. Bullinger, D. Späth, S. Kayser, M. Zucknick, K. Götze and 4 more. Journal of Clinical Oncology, 2010

810 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/bd12bc6cde82026a80bfa0d956c830dc2fb2e3f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

H. Kantarjian

In Molecular Biology

Citations in the corpus

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation (2010, background): “, 2009), occasional rare AML patients have been reported with concurrent mutations in both IDH1 and IDH2 (Paschka et al., 2010).”
Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML (2018, background): “Relapse within 1 yr after initial therapy 13 (10) 17 (9) —”
The Definition of Primary and Secondary Glioblastoma (2012, background): “Exceptions are central chondrosarcomas (~55%) (16), intrahepatic cholangio-carcinomas (23%) (17), acute myeloid leukemia (AML; 15–20%) (18-23), angioimmunoblastic T-cell lymphoma (AITL; ~20%) (24) malignant melanoma (~10%) (25), and anaplastic thyroid cancer (~10%) (26).”
SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution (2014, background): “Determining stability of inferred subclones as a function (a) of number of variants, (b) of inter-cluster separation, and (c) of clustering method from AML sample.”
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. (2017, neutral): “Platelets, 310(9)/L 39 (1-372) 44 (1-507) 45 (1-644)”